INVA - Innoviva, Inc.

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod.

Aug 11, 2026 12:05 PM • businesswire.com

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.

Aug 06, 2026 03:31 AM • seekingalpha.com

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.

Aug 05, 2026 05:36 PM • zacks.com

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements. “Innoviva delivered an.

Aug 05, 2026 12:05 PM • businesswire.com

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

Aug 03, 2026 06:05 AM • marketbeat.com

Dimensional Fund Advisors LP Acquires 76,026 Shares of Innoviva, Inc. $INVA

Dimensional Fund Advisors LP grew its holdings in shares of Innoviva, Inc. (NASDAQ: INVA) by 1.7% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,436,427 shares of the biotechnology company's stock after acquiring an additional 76,026 shares during the period. Dimensional Fund Advisors LP owned

Jul 29, 2026 12:17 AM • defenseworld.net

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines u

Jun 18, 2026 05:00 AM • gurufocus.com

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact.

Jun 18, 2026 04:00 AM • businesswire.com

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent S.

Jun 16, 2026 04:00 AM • businesswire.com

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jun 08, 2026 01:38 PM • seekingalpha.com

Innoviva to Participate in Upcoming Investor Conferences

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica

Jun 01, 2026 08:01 AM • gurufocus.com

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference.

Jun 01, 2026 07:00 AM • businesswire.com

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

May 29, 2026 02:35 PM • fool.com

Innoviva (INVA) Tops Q1 Earnings Estimates

Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.

May 06, 2026 06:45 PM • zacks.com

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. “We delivered a strong.

May 06, 2026 12:05 PM • businesswire.com

Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates

Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.

Apr 30, 2026 04:41 AM • zacks.com

Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to

Apr 18, 2026 12:10 AM • defenseworld.net

3 Bargain-Cheap Small Caps Worth a Second Look

The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.

Apr 09, 2026 04:24 AM • marketbeat.com

Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $20.50 and traded as high as $23.15. Innoviva shares last traded at $23.02, with a volume of 450,806 shares. Analyst Upgrades and Downgrades

Apr 06, 2026 11:20 PM • defenseworld.net

Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80

Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to

Mar 26, 2026 09:31 PM • defenseworld.net

Innoviva price target lowered to $34 from $36 at Cantor Fitzgerald

$34.00 (was $20.63)

Cantor Fitzgerald

Aug 07, 2026 08:49 AM • TheFly

Innoviva price target raised to $42 from $35 at BTIG

$42.00 (was $23.49)

BTIG

May 07, 2026 08:06 AM • TheFly

Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook

$32.00 (was $23.98)

Steve Seedhouse · Cantor Fitzgerald

Feb 26, 2026 09:24 AM • StreetInsider

Innoviva initiated with a Buy at BTIG

$35.00 (was $22.70)

BTIG

Feb 17, 2026 06:10 AM • TheFly

Innoviva price target raised to $46 from $45 at H.C. Wainwright

$46.00 (was $20.14)

H.C. Wainwright

Dec 16, 2025 06:11 AM • TheFly

Innoviva initiated with a Sell at Goldman Sachs

$17.00 (was $19.03)

Goldman Sachs

Sep 30, 2025 05:12 AM • TheFly

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

$35.00 (was $19.93)

Trevor Allred · Oppenheimer

Aug 11, 2025 07:53 AM • Benzinga

Innoviva initiated with an Outperform at Scotiabank

$55.00 (was $17.64)

Scotiabank

Mar 07, 2025 07:00 AM • TheFly

Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $13

$13.00 (was $14.72)

Morgan Stanley

Aug 08, 2022 05:38 AM • Benzinga

Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $12

$12.00 (was $14.37)

Morgan Stanley

Jul 15, 2022 07:05 AM • Benzinga